interferon β biobetter (ABN101) / Abion - LARVOL DELTA

Relative Quantitative Analysis of Site-Specific N-Linked Glycosylation in Hyperglycosylated Interferon-β via Mass Spectrometry. (PubMed, Int J Mol Sci) - "Protease digestion conditions were optimized to improve recovery of site-specific glycopeptides, with chymotrypsin identified as the most effective enzyme for resolving glycopeptides from individual glycosylation sites...Molecular modeling further suggested that the additional glycan at Asn25 may enhance structural stability and receptor-binding affinity. These results demonstrate an integrative strategy for accurate glycan characterization in multi-site glycoproteins relevant to biotherapeutic development."

Journal • IFNB1

Inhalable Interferon-beta Bio-better, ABN101 Dry Powder, Inhibits and Reduces the Infection of Respiratory Viruses in Non-human Primates (NHPs) (ATS 2024) - "Oseltamivir and nirmatrelvir/molnupiravir were dosed via oral gavage as positive control for respective viruses. Interestingly, ABN101 DP pre-treated group showed the lowest virus titers for both viruses, which indicated that ABN101 DP can be utilized as prophylactic treatment for respiratory viruses. Conclusions In conclusion, ABN101 DP delivered through inhalation can reduce virus titers of IAV and SARS-CoV-2 in NHPs, which may prove ABN101 DP has the potential broad-spectrum anti-respiratory virus therapeutics for pandemic preparedness."

Late-breaking abstract • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases • IFNB1

A Novel Dry Powder, ABN101 Broad-spectrum, Anti-viral Inhaler to Avoid and Treat Global Respiratory Virus Pandemics (ATS 2023) - "Conclusions In conclusion, ABN101 DP can penetrate tertiary airways and remains available in the BALF up to 24H following IH treatment, whereas the effect was much shorter when delivered by IV, and not observed in the BALF. Abion is determining biomarkers to measure prophylactic and therapeutic efficacy through IH in AGMs."

Clinical • Late-breaking abstract • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • IFNB1